Lhasa Limited shared knowledge shared progress

Archive

This is a library of Lhasa's blog articles. 

  • Using existing data better, relying less on animal testing
    Clock: less than 5 minutesless than 5 minutes

    Using existing data better and relying less on animal testing

    I recently read that by 2025, 36% of world data will be healthcare data. (Yes, thirty-six percent!). Considering this statistic, now more than ever, it is important that we are working to ensure existing data is utilised to make better safety assessment decisions more quickly - whilst also relying less on animal testing.

    04 August 2022

  • 5 things you should know about the data in the Lhasa Carcinogenicity Database (LCDB)
    Clock: 5 minutes5 minutes

    5 things you should know about the data in the Lhasa Carcinogenicity Database (LCDB)

    Would your toxicology assessments benefit from free access to long-term carcinogenicity study data? The Lhasa Carcinogenicity Database (LCDB) is a widely used, free resource of long-term carcinogenicity study data.

    In this article we explore 5 things you should know about the data in the LCDB.

    25 May 2022

  • Meeting ICH S1 and reducing animal testing through AOPs; Have you read this?
    Clock: less than 5 minutesless than 5 minutes

    Meeting ICH S1 and reducing animal testing through AOPs; Have you read this?

    “As Adverse Outcome Pathways (AOPs) move from being an interesting scientific concept, to a useful practical application tool, this is an exciting time for both industry and Lhasa” … Regular Lhasa blog readers will have read this statement within our September blog “Shaping Lhasa Limited’s scientific direction through collaboration”.

    It is with great excitement that this month we can provide you with another pioneering update on the topic of our AOP work; Our paper, “Employing an adverse outcome pathway framework for weight-of-evidence assessment with application to the ICH S1B guidance addendum” has now been published in the Regulatory Toxicology and Pharmacology Journal!

    03 November 2021

  • Shaping Lhasa Limited’s scientific direction through collaboration
    Clock: less than 5 minutesless than 5 minutes

    Shaping Lhasa Limited’s scientific direction through collaboration

    “Our technology is designed by scientists, for scientists, in collaboration with industry stakeholders and regulators” …

    At Lhasa Limited we often talk about the importance of industry and regulatory input in shaping our scientific direction. This article discusses a few key areas of involvement and collaboration plus, focuses on a recent example, on the topic of Adverse Outcome Pathways (AOPs). Read on to learn more and find out how you can get involved!

    09 September 2021

  • Derek Nexus Achieving high accuracy with high coverage
    Clock: less than 5 minutesless than 5 minutes

    Derek Nexus – Achieving high accuracy with high coverage [an infographic]

    In this blog piece, we explore how Derek Nexus performs when evaluated against 7 different in silico skin sensitisation models.

    11 August 2021

  • A laptop and molecule on a blue background
    Clock: 5 minutes5 minutes

    Predicting forced degradation pathways: Learning how to get the most out of Zeneth

    Are you getting the most out of Zeneth, Lhasa’s expert, knowledge-based in silico software for the prediction of forced degradation pathways of organic active pharmaceutical ingredients (APIs)? 

    19 April 2021

  • Moving with the times; Lhasa’s Cloud offerings
    Clock: less than 5 minutesless than 5 minutes

    Moving with the times; Lhasa’s cloud offerings

    In a world where we are all striving for progress, technology is also advancing quickly.

    Like many organisations across the life sciences industry – evidenced by the 82 Amazon Web Service (AWS) life sciences case studies -  Lhasa has adopted cloud, Software as a Service (SaaS), options across three notable areas...

    30 March 2021

  • Effiris blog image Feb2021
    Clock: less than 5 minutesless than 5 minutes

    How to better anticipate and mitigate adverse drug reactions [an infographic]

    Are you interested in using your data to anticipate and mitigate adverse drug reactions? The Effiris consortium - currently composed of Takeda, GSK and UCB - is working to achieve just that.

    17 February 2021

  • Image for solubility purge best practice blog
    Clock: 5 minutes5 minutes

    Lhasa Limited collaborates with industry and regulators to define solubility purge best practice

    Key to the regulatory acceptance of purge arguments is the conservatism within the purge factor scoring system, which for reactivity purge has been demonstrated across a number of publications and is consistently implemented across the pharmaceutical industry through the development of a collective understanding of and how they should be applied.

    Likewise, when volatility purge scoring is relatively simple to understand and apply, particularly using the scoring thresholds originally proposed by Teasdale et al.

    However, through our interactions with Mirabilis users, regulators, and other members of the purge community, it has become increasingly apparent that the same cannot be said of solubility purge scoring. Lhasa have therefore identified the huge value to the community of developing an accepted best practice, incorporating both the application of solubility purge scoring and, where appropriate, provision of a clear justification of the purge factor assigned.

    29 October 2020

  • Vaccine image rendered
    Clock: 5 minutes5 minutes

    Lhasa Limited supports an international initiative in the fight against COVID-19

    Coronaviruses are a large family of viruses which can affect humans or other species and can range anywhere from a mild illness such as the common cold to more severe illnesses such as Severe Acute Respiratory Syndrome (SARS). Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

    25 June 2020

© 2022 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.